DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (6.4), the stock would be worth ¥26.73 (49% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.3 | ¥17.98 |
0%
|
| 3-Year Average | 6.4 | ¥26.73 |
+49%
|
| 5-Year Average | 10.4 | ¥43.2 |
+140%
|
| Industry Average | 17.1 | ¥71.16 |
+296%
|
| Country Average | 20.8 | ¥86.72 |
+382%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
20.5B CNY | 4.3 | 18 | |
| ZA |
C
|
Clicks Group Ltd
JSE:CLS
|
71B ZAR | 21.2 | 21.9 | |
| ZA |
D
|
Dis-Chem Pharmacies Ltd
JSE:DCP
|
32.2B ZAR | 23.3 | 26.1 | |
| US |
|
Walgreens Boots Alliance Inc
NASDAQ:WBA
|
10.4B USD | 11 | -1.6 | |
| BR |
|
Raia Drogasil SA
BOVESPA:RADL3
|
39.7B BRL | 18.8 | 30 | |
| JP |
|
Tsuruha Holdings Inc
TSE:3391
|
939.9B JPY | 5.3 | 22 | |
| JP |
|
MatsukiyoCocokara & Co
TSE:3088
|
915.8B JPY | 11.1 | 16.3 | |
| SA |
|
Al Nahdi Medical Company SCJSC
SAU:4164
|
16.8B SAR | 15.5 | 20.2 | |
| CN |
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
29.9B CNY | 8.1 | 18.2 | |
| JP |
|
Welcia Holdings Co Ltd
TSE:3141
|
657.7B JPY | 10.7 | 34.3 | |
| JP |
S
|
Sugi Holdings Co Ltd
TSE:7649
|
588.7B JPY | 6.5 | 13.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
DaShenLin Pharmaceutical Group Co Ltd
Glance View
DaShenLin Pharmaceutical Group Co., Ltd. is a fascinating entity woven into the intricate fabric of China's rapidly evolving healthcare landscape. Stemming from humble origins, the company has blossomed into a significant player in the pharmaceutical industry. DaShenLin's business model adeptly combines the traditional with the modern, strategically positioning itself across the supply and distribution spectrum. Primarily, it operates through an extensive retail network, boasting a formidable chain of pharmacies thoughtfully dotted across various provinces. These pharmacies are more than mere outlets; they serve as community health sanctuaries offering an array of pharmaceutical products and health consultations. The company's commitment to traditional Chinese medicine sets it apart, further establishing a niche by fusing age-old healing practices with contemporary medicinal needs. The company's revenue streams are as diverse as its product offerings. Predominantly, it derives income from the direct sale of pharmaceuticals, encompassing both Western drugs and traditional Chinese medicines. Additionally, DaShenLin capitalizes on its robust wholesale operations, providing a steady pipeline of medicinal products to regional hospitals and clinics. The company thrives on its comprehensive supply chain, which ensures an uninterrupted flow of goods from production to consumers' hands. With a keen emphasis on quality and efficacy, DaShenLin continuously invests in research and development, fostering innovation within its product lines. This strategic focus not only reinforces consumer trust but also secures its competitive edge within a dynamic market landscape.